Take the Precision Oncology Coding Challenge
Here’s how to understand CPT® and ICD-10-CM coding for cancer genetic testing. Precision medicine is an advanced approach to cancer care that tailors prevention, diagnosis, and treatment to unique genetic, molecular, and cellular patient characteristics. The approach has changed the way cancer is diagnosed and treated because providers can now use genetic and genomic testing to identify specific mutations that drive tumor growth. These tests help determine hereditary cancer risk, guide targeted therapy selection, and monitor disease progression. But as genetic testing for cancer expands, coding and reimbursement has become significantly more complex. Coders, billers, laboratories, and revenue cycle teams must understand not only which CPT® codes apply, but also the science behind the testing, the clinical purpose of the procedure, and the ICD-10-CM codes that support medical necessity. Here’s what you need to know to stay ahead of the curve. Understand the Science Behind Cancer Genetic Testing Cancer develops when genes inside cells become damaged or altered, causing cells to grow uncontrollably. Some mutations, called germline mutations, are inherited from parents and increase a person’s lifetime cancer risk. Germline testing is usually performed using blood or saliva samples and is commonly associated with hereditary cancer syndromes such as BRCA-related breast and ovarian cancer or Lynch syndrome. Other mutations develop over time within tumor cells and are not inherited. These are called somatic mutations. Somatic testing analyzes tumor tissue to help determine which therapies may work best. Modern oncology testing may evaluate single genes, multiple biomarkers, or hundreds of genes simultaneously. These tests can identify mutations, gene rearrangements, deletions, amplifications, and treatment-resistant tumor changes. Common Testing Technologies Several technologies are commonly used in oncology molecular testing: Look to These Codes for Oncology Genetic Testing CPT® coding for molecular pathology has expanded rapidly as oncology testing has become more sophisticated. These codes comprise a large section of the CPT® book. Tier 1 Molecular Pathology Codes (81105-81383) Tier 1 codes describe commonly performed, analyte- and gene-specific tests. Each code corresponds to a specific gene or targeted mutation commonly associated with breast, ovarian, lung, and colorectal cancer, and melanoma. Examples include BRCA1/BRCA2 testing, EGFR mutation analysis, KRAS testing, and BRAF mutation analysis. Generally, only 1 unit of service can be reported per Tier 1 molecular pathology code when testing a specimen from a single source. However, providers should not report multiple individual codes if a single comprehensive genomic sequencing procedure (GSP) code or specific panel code describes the assay. Tier 2 Molecular Pathology Codes (81400-81408) Tier 2 codes are used for uncommon gene testing; less common, lower-volume molecular testing; and technically complex analyses. Rather than detailing a specific gene, Tier 2 codes are organized sequentially by the level of technical complexity and the interpretive effort required to perform the assay. As with Tier 1 codes, assign only 1 unit for each listed Tier 2 code. At the end of this section in the CPT® book, there is an unlisted, fallback code: 81479 (Unlisted molecular pathology procedure). If the specific gene or analyte being tested is neither represented by a Tier 1 code nor accurately described in any Tier 2 code, you’ll use 81479. Just make sure the specific gene tested is documented and that clinicians provide medical records demonstrating the test’s analytic validity and clinical utility. Genomic Sequencing Procedures (GSPs) (81410-81479) These tests sequence multiple genes simultaneously, often using NGS. Common applications include solid tumor panels, hematologic malignancy panels, hereditary cancer panels, and broad genomic profiling. Multianalyte Assays With Algorithmic Analyses (MAAA) (81490-81599) MAAA tests combine multiple biomarkers with mathematical algorithms to generate clinical scores or risk assessments. These tests may help predict cancer recurrence risk, treatment response, or disease prognosis. Proprietary Laboratory Analyses (PLA) PLA codes identify laboratory-specific proprietary tests. They are a specialized subsection of CPT® and are structured alphanumerically as four numbers followed by the letter “U.” These codes are updated quarterly, are tied to specific laboratories or assays, and are increasingly used for advanced genomic testing. PLA codes typically do not include a physician work component, as they are strictly for analysis by the proprietary lab. These codes include MAAA and GSPs. Let ICD-10-CM Codes Determine Necessity ICD-10-CM coding for oncology genetic testing generally reflects one or more of the following when appropriate: active malignancy, family history, personal history, genetic susceptibility, or hereditary cancer risks. Diagnosis coding can also be used to screen asymptomatic individuals undergoing preventive evaluation. Understanding the distinction between these categories helps coders assign the most accurate diagnosis codes and avoid denials related to insufficient medical necessity. Take These Tips When Coding for Active Malignancy In oncology, molecular and genomic testing often supports identification of actionable mutations, the selection of targeted therapies, determination of treatment resistance, and monitoring disease progression. When testing is directly related to management of an existing cancer, active malignancy codes usually serve as the primary diagnosis. These codes are typically found in the C00-C96 (Malignant neoplasms) range of ICD-10-CM and identify the specific cancer type and site. Family History of Cancer? Use These Codes Family history codes are used when the patient does not currently have cancer but has biologically related family members with malignancies associated with inherited cancer syndromes. These codes typically fall under the Z80.- (Family history of primary malignant neoplasm) category. Family history is particularly important in hereditary cancer testing because it may establish medical necessity for evaluating inherited mutations such as BRCA1/BRCA2, Lynch syndrome genes, TP53 (tumor protein p53), and PALB2 (Partner and Localizer of BRCA2). Payers frequently require strong family history documentation before approving hereditary cancer panels. Code for Personal History of Cancer When Still Relevant Personal history codes apply when the patient has a previous cancer diagnosis that is no longer considered active but remains clinically relevant. Genetic testing may still be medically necessary in cancer survivors because prior malignancies can indicate hereditary cancer syndromes, elevated recurrence risk, risk for secondary primary cancers, and familial implications for relatives. Codes commonly used to report a personal history of cancer come from the Z85.- (Personal history of malignant neoplasm) category. Before using one, you should verify that documentation supports that the cancer is no longer under active treatment and that there is no evidence of current disease. Documentation should also state the clinical rationale for genetic evaluation. Go to This Group to Code Genetic Susceptibility to Disease Genetic susceptibility codes identify patients with documented inherited mutations associated with increased cancer risk, with codes generally found within the Z15.- (Genetic susceptibility to disease) category. Examples include genetic susceptibility to malignant neoplasm of the breast and genetic susceptibility to ovarian cancer. These diagnoses may be assigned when a pathogenic mutation has already been identified, predictive testing confirms inherited risk, or surveillance or prophylactic management is underway. Coders should ensure documentation clearly confirms the genetic finding rather than merely suspected risk. Use Several Codes for Hereditary Cancer Risk Patients with a hereditary cancer risk have an increased likelihood of inherited cancer syndromes based on clinical indicators, pedigree analysis, ethnicity, or risk assessment tools. This category may involve a combination of family history codes, genetic susceptibility codes, and counseling encounter codes. Patients may qualify for testing even without a personal cancer diagnosis if risk factors strongly suggest inherited predisposition, such as multiple relatives with related cancers, some early-onset cancers, bilateral or multiple primary tumors, and known familial mutations. Look to the Z12.- Group for Screening Indication Codes You’ll use screening codes when your provider uses genetic testing or related services in asymptomatic individuals undergoing preventive evaluation. These codes often originate from the Z12.- (Encounter for screening for malignant neoplasms) category. In oncology, screening indications may overlap with high-risk populations, preventive medicine, and early detection initiatives. Payer policies frequently differ between preventive screening and diagnostic genetic testing, making accurate coding especially important. Keep Pace With Genomic Innovations in Oncology Precision oncology has transformed cancer care by allowing providers to personalize treatment based on a patient’s genetic profile. At the same time, oncology molecular testing has become one of the most complex areas in healthcare coding and reimbursement. As NGS, liquid biopsy, and proprietary genomic assays continue to expand, accurate documentation, proper code selection, and payer policy awareness will remain essential for compliance and reimbursement success. Sarah Jakubowski, RHIT, CPC, CPMA, Consultant,
Pinnacle Enterprise Risk Consulting Services
